PCSK9 Inhibitor Use in the Real World: Data From the National Patient‐Centered Research Network

BACKGROUND: PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors effectively lower LDL (low‐density lipoprotein) cholesterol and have been shown to reduce cardiovascular outcomes in high‐risk patients. We used real‐world electronic health record data to characterize use of PCSK9 inhibito...

Descripción completa

Detalles Bibliográficos
Autores principales: Chamberlain, Alanna M., Gong, Yan, Shaw, Kathryn McAuliffe, Bian, Jiang, Song, Wen‐Liang, Linton, MacRae F., Fonseca, Vivian, Price‐Haywood, Eboni, Guhl, Emily, King, Jordan B., Shah, Rashmee U., Puro, Jon, Shenkman, Elizabeth, Pawloski, Pamala A., Margolis, Karen L., Hernandez, Adrian F., Cooper‐DeHoff, Rhonda M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512121/
https://www.ncbi.nlm.nih.gov/pubmed/31020929
http://dx.doi.org/10.1161/JAHA.118.011246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6512121/
https://www.ncbi.nlm.nih.gov/pubmed/31020929
http://dx.doi.org/10.1161/JAHA.118.011246

Ejemplares similares